The New York Academy of Sciences symposium will
highlight cutting edge research across the fields of inflammation,
infection, and tissue regeneration, with focus on novel resolution
mediators and mechanisms
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) (“Corbus” or
the “Company”), a Phase 3 clinical-stage pharmaceutical company
focused on the development and commercialization of novel
therapeutics to treat rare, chronic and serious inflammatory
diseases, announced that it will be presenting at the Resolution of
Inflammation, Infection and Tissue Regeneration Conference in
partnership with the New York Academy of Sciences (NYAS), taking
place on Tuesday, June 26, 2018 in New York City.
Dr. Mark Tepper, Corbus’ President and Chief
Scientific Officer, will present on Tuesday, June 26th in a talk
titled, “Resolution of Inflammatory/Fibrotic Diseases by Lenabasum
through activation of the Endocannabinoid Specialized
Pro-Resolution Mediator Pathway,” and will sit on a panel titled,
“Barriers to Translation in Inflammatory Disease.”
The conference will convene 18 preeminent
researchers who will discuss mechanisms of inflammation, tissue
repair and regeneration, and explore existing challenges to
clinical approaches. Keynote speakers include:
- Charles N. Serhan, PhD, DSc, Brigham and
Women’s Hospital, Harvard Medical School and a member of the
Scientific Advisory Board of Corbus
- Catherine Godson, PhD, University College
Dublin
- Kevin J. Tracey, MD, The Feinstein Institute
for Medical Research
“Advancements in scientific research and drug
discovery is rapidly shaping our understanding of the important
role that resolution plays in inflammation, infection and tissue
regeneration, otherwise known as Resolution Pharmacology,” said Dr.
Tepper. “We are proud to collaborate in facilitating this important
symposium, and we look forward to productive discussions to further
advance the field.”
To register for the
conference or to view the live webcast click on the link
here.
Note to journalists: Press passes for this program are available
upon request. Please email: MGentile@nyas.org or
RBirchard@nyas.org.
About New York Academy of Sciences
The New York Academy of Sciences (NYAS) is an
independent, not-for-profit organization that since 1817 has been
committed to advancing science, technology, and society worldwide.
With more than 20,000 members around the world, the Academy is
creating a global community of science for the benefit of humanity.
The Academy's core mission is to advance scientific knowledge,
positively impact the major global challenges of society with
science-based solutions and increase the number of scientifically
informed individuals in society at large. Please visit us online
at www.nyas.org.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a Phase
3 clinical-stage pharmaceutical company focused on the development
and commercialization of novel therapeutics to treat rare, chronic,
and serious inflammatory and fibrotic diseases. The Company's lead
product candidate, lenabasum, is a novel, synthetic oral
endocannabinoid-mimetic drug designed to resolve chronic
inflammation and fibrotic processes. Lenabasum is currently being
evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis,
and systemic lupus erythematosus.
For more information, please visit
www.CorbusPharma.com and connect with the Company on Twitter,
LinkedIn, Google+ and Facebook.
Forward-Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as
amended, including those relating to the Company's product
development, clinical and regulatory timelines, market opportunity,
competitive position, possible or assumed future results of
operations, business strategies, potential growth opportunities and
other statement that are predictive in nature. These
forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management's current beliefs and
assumptions.
These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
"expect," "anticipate," "intend," "plan," "believe," "estimate,"
"potential, "predict," "project," "should," "would" and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company's filings with the
Securities and Exchange Commission. Prospective investors are
cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this press release.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Source: Corbus Pharmaceuticals Holdings, Inc.
###
Investor Contacts:
Institutional Investor Inquiries
Ted Jenkins, Senior Director, Investor Relations and Communications
Corbus Pharmaceuticals, Inc.
Phone: +1 (617) 415-7745
Email: ir@corbuspharma.com
All Other Investor Inquiries
Jenene Thomas
Jenene Thomas Communications, LLC
Phone: +1 (833) 475-8247
Email: crbp@jtcir.com
Media Contact
Eliza Schleifstein
Scient Public Relations
Phone: + 1 (917) 763-8106
Email: eliza@scientpr.com
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Sep 2023 to Sep 2024